Cargando…

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys

BACKGROUND: Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent data from two nationwide cohorts of patients suggested no gender difference as reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrannini, Giulia, De Bacquer, Dirk, Vynckier, Pieter, De Backer, Guy, Gyberg, Viveca, Kotseva, Kornelia, Mellbin, Linda, Norhammar, Anna, Tuomilehto, Jaakko, Wood, David, Rydén, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879645/
https://www.ncbi.nlm.nih.gov/pubmed/33573665
http://dx.doi.org/10.1186/s12933-021-01233-6
_version_ 1783650554925285376
author Ferrannini, Giulia
De Bacquer, Dirk
Vynckier, Pieter
De Backer, Guy
Gyberg, Viveca
Kotseva, Kornelia
Mellbin, Linda
Norhammar, Anna
Tuomilehto, Jaakko
Wood, David
Rydén, Lars
author_facet Ferrannini, Giulia
De Bacquer, Dirk
Vynckier, Pieter
De Backer, Guy
Gyberg, Viveca
Kotseva, Kornelia
Mellbin, Linda
Norhammar, Anna
Tuomilehto, Jaakko
Wood, David
Rydén, Lars
author_sort Ferrannini, Giulia
collection PubMed
description BACKGROUND: Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent data from two nationwide cohorts of patients suggested no gender difference as regards the risk for diabetes-related CV complications but indicated the presence of a gender disparity in risk factor management. The aim of this study was to investigate gender differences in screening for dysglycaemia, cardiovascular risk factor management and prognosis in dysglycemic CAD patients. METHODS: The study population (n = 16,259; 4077 women) included 7998 patients from the ESC-EORP EUROASPIRE IV (EAIV: 2012–2013, 79 centres in 24 countries) and 8261 patients from the ESC-EORP EUROASPIRE V (EAV: 2016–2017, 131 centres in 27 countries) cross-sectional surveys. In each centre, patients were investigated with standardised methods by centrally trained staff and those without known diabetes were offered an oral glucose tolerance test (OGTT). The first of CV death or hospitalisation for non-fatal myocardial infarction, stroke, heart failure or revascularization served as endpoint. Median follow-up time was 1.7 years. The association between gender and time to the occurrence of the endpoint was evaluated using Cox survival modelling, adjusting for age. RESULTS: Known diabetes was more common among women (32.9%) than men (28.4%, p < 0.0001). OGTT (n = 8655) disclosed IGT in 17.2% of women vs. 15.1% of men (p = 0.004) and diabetes in 13.4% of women vs. 14.6% of men (p = 0.078). In both known diabetes and newly detected dysglycaemia groups, women were older, with higher proportions of hypertension, dyslipidaemia and obesity. HbA1c was higher in women with known diabetes. Recommended targets of physical activity, blood pressure and cholesterol were achieved by significantly lower proportions of women than men. Women with known diabetes had higher risk for the endpoint than men (age-adjusted HR 1.22; 95% CI 1.04–1.43). CONCLUSIONS: Guideline-recommended risk factor control is poorer in dysglycemic women than men. This may contribute to the worse prognosis in CAD women with known diabetes.
format Online
Article
Text
id pubmed-7879645
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78796452021-02-17 Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys Ferrannini, Giulia De Bacquer, Dirk Vynckier, Pieter De Backer, Guy Gyberg, Viveca Kotseva, Kornelia Mellbin, Linda Norhammar, Anna Tuomilehto, Jaakko Wood, David Rydén, Lars Cardiovasc Diabetol Original Investigation BACKGROUND: Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent data from two nationwide cohorts of patients suggested no gender difference as regards the risk for diabetes-related CV complications but indicated the presence of a gender disparity in risk factor management. The aim of this study was to investigate gender differences in screening for dysglycaemia, cardiovascular risk factor management and prognosis in dysglycemic CAD patients. METHODS: The study population (n = 16,259; 4077 women) included 7998 patients from the ESC-EORP EUROASPIRE IV (EAIV: 2012–2013, 79 centres in 24 countries) and 8261 patients from the ESC-EORP EUROASPIRE V (EAV: 2016–2017, 131 centres in 27 countries) cross-sectional surveys. In each centre, patients were investigated with standardised methods by centrally trained staff and those without known diabetes were offered an oral glucose tolerance test (OGTT). The first of CV death or hospitalisation for non-fatal myocardial infarction, stroke, heart failure or revascularization served as endpoint. Median follow-up time was 1.7 years. The association between gender and time to the occurrence of the endpoint was evaluated using Cox survival modelling, adjusting for age. RESULTS: Known diabetes was more common among women (32.9%) than men (28.4%, p < 0.0001). OGTT (n = 8655) disclosed IGT in 17.2% of women vs. 15.1% of men (p = 0.004) and diabetes in 13.4% of women vs. 14.6% of men (p = 0.078). In both known diabetes and newly detected dysglycaemia groups, women were older, with higher proportions of hypertension, dyslipidaemia and obesity. HbA1c was higher in women with known diabetes. Recommended targets of physical activity, blood pressure and cholesterol were achieved by significantly lower proportions of women than men. Women with known diabetes had higher risk for the endpoint than men (age-adjusted HR 1.22; 95% CI 1.04–1.43). CONCLUSIONS: Guideline-recommended risk factor control is poorer in dysglycemic women than men. This may contribute to the worse prognosis in CAD women with known diabetes. BioMed Central 2021-02-11 /pmc/articles/PMC7879645/ /pubmed/33573665 http://dx.doi.org/10.1186/s12933-021-01233-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Ferrannini, Giulia
De Bacquer, Dirk
Vynckier, Pieter
De Backer, Guy
Gyberg, Viveca
Kotseva, Kornelia
Mellbin, Linda
Norhammar, Anna
Tuomilehto, Jaakko
Wood, David
Rydén, Lars
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
title Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
title_full Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
title_fullStr Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
title_full_unstemmed Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
title_short Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
title_sort gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the esc-eorp euroaspire surveys
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879645/
https://www.ncbi.nlm.nih.gov/pubmed/33573665
http://dx.doi.org/10.1186/s12933-021-01233-6
work_keys_str_mv AT ferranninigiulia genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT debacquerdirk genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT vynckierpieter genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT debackerguy genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT gybergviveca genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT kotsevakornelia genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT mellbinlinda genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT norhammaranna genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT tuomilehtojaakko genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT wooddavid genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT rydenlars genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys
AT genderdifferencesinscreeningforglucoseperturbationscardiovascularriskfactormanagementandprognosisinpatientswithdysglycaemiaandcoronaryarterydiseaseresultsfromtheesceorpeuroaspiresurveys